Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid ...

The following is a summary of “A Novel Molecular Regulatory Network in Bone Marrow Mesenchymal Stem Cells for Age-Related Osteoporosis,” published in the March 2025 issue of Clinical Endocrinology by ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Scientists have unveiled a revolutionary method for mass-producing high-quality human mitochondria, potentially transforming ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil ® (remestemcel-L) the first mesenchymal stromal cell ...

The possibility of gaining access to life-changing stem cell therapy could finally be in reach for many in the region, thanks ...

Nature Cell Co. Ltd. won U.S. FDA breakthrough therapy designation of its autologous adipose-derived mesenchymal stem cell therapy, Jointstem, March 20, becoming the first Korean company to earn the ...

Protara Therapeutics (NASDAQ:TARA – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will ...

The pluripotent and multipotent stem cells are found in the bone marrow, which can differentiate into any tissue in the body.